Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment na√Øve Advanced meRkel Cell cArcinoma (MCC)
This is an open label, multicenter, phase II study evaluating the activity and safety of pembrolizumab combined with cisplatin/carboplatin and etoposide as first line treatment in patients with advanced MCC.
Merkel Cell Carcinoma
DRUG: Pembrolizumab, Etoposide, Cisplatin or Carboplatin
To assess the safety and antitumor activity of pembrolizumab combined with cisplatin/carboplatin and etoposide as first line treatment in MCC., ORR, that will be defined as the percentage of patients achieving complete response (CR) or partial response (PR) according to RECIST 1.1 criteria, 48 months
To assess safety and efficacy of pembrolizumab combined with chemotherapy as first line treatment in patients with MCC, Incidence of Serius Adverse Events (SAE), 48 months|To assess safety and efficacy of pembrolizumab combined with chemotherapy as first line treatment in patients with MCC, Incidence and severity of Adverse Events (AEs) according to NCI Common Terminology criteria Adverse Event (CTCAE), version 5.0, 48 months|To assess safety and efficacy of pembrolizumab combined with chemotherapy as first line treatment in patients with MCC, Incidence and severity of Immune-mediated Adverse Events (imAE), 48 months|To assess safety and efficacy of pembrolizumab combined with chemotherapy as first line treatment in patients with MCC, Overall Survival (OS) that will be measured from the date of starting therapy to the date of death by any cause, 48 months|To assess safety and efficacy of pembrolizumab combined with chemotherapy as first line treatment in patients with MCC, Progression Free Survival (PFS) that will be measured from the date of starting therapy to the date of disease progression or death., 48 months|To assess safety and efficacy of pembrolizumab combined with chemotherapy as first line treatment in patients with MCC, Duration of Response (DOR) that will be measured from the date of the first response to disease progression or death in those patients who achieved a CR o PR during study treatment., 48 months
This is an open label, multicenter, phase II study evaluating the activity and safety of pembrolizumab combined with cisplatin/carboplatin and etoposide as first line treatment in patients with advanced MCC.